Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105.1 USD | -0.94% | -3.28% | -14.59% |
Financials (USD)
Sales 2024 * | 4.05B | Sales 2025 * | 4.36B | Capitalization | 6.69B |
---|---|---|---|---|---|
Net income 2024 * | 430M | Net income 2025 * | 597M | EV / Sales 2024 * | 2.51 x |
Net Debt 2024 * | 3.48B | Net Debt 2025 * | 2.23B | EV / Sales 2025 * | 2.05 x |
P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
12.3
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -0.94% | ||
1 week | -3.28% | ||
Current month | -5.14% | ||
1 month | -4.02% | ||
3 months | -20.57% | ||
6 months | -10.62% | ||
Current year | -14.59% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 254 M€ | +12.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 105.1 | -0.94% | 624,446 |
24-05-24 | 106.1 | +2.04% | 675,815 |
24-05-23 | 103.9 | -1.49% | 796,300 |
24-05-22 | 105.5 | -1.36% | 950,129 |
24-05-21 | 107 | -1.52% | 594,542 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.59% | 6.69B | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- JAZZ Stock